Viewing Study NCT00963534

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:32 AM
Ignite Modification Date: 2026-05-04 @ 8:41 PM
Study NCT ID: NCT00963534
Status: COMPLETED
Last Update Posted: 2018-03-12
First Post: 2009-08-20
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Sponsor: Lund University Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mantle Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Mantle cell lymphoma View
None Lenalidomide View
None Bendamustine View
None Rituximab View
None Nordic Lymphoma Group View
None MTD for lenalidomide View
None Untreated patients View
None Patients with mantle cell lymphoma, age over 65 years View